|Bid||163.49 x 1100|
|Ask||627.00 x 800|
|Day's range||619.87 - 641.45|
|52-week range||545.00 - 832.70|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||2.85|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||918.75|
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.
HERCULES, Calif., January 05, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in a virtual Fireside Chat during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 PM (PST).
Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.